Symposium highlights new emerging therapies for the treatment of lupus

October 18, 2004

WHAT & WHY:
Lupus treatments will be highlighted during a symposium at this year's American College of Rheumatology (ACR) annual scientific meeting in San Antonio, TX. The symposium, "The Emerging Role of Antimetabolites in the Treatment of Nonrenal Systemic Lupus Erythematosus (SLE)," will include discussion of non-FDA approved agents under investigation for the treatment of renal or nonrenal SLE.

Additional discussion topics include current FDA approved, and newer treatments for SLE, and their associated risk: benefit profiles, benefits of newer treatments over current "gold standards" of SLE therapy, the role of antimetabolites in treating renal and nonrenal SLE and the dermatologic, cardiovascular and central nervous system issues in managing patients with SLE.

Lupus statistics:
  • Approximately 1.4 million Americans have been diagnosed with lupus
  • Women are 8-10 times more likely to suffer from lupus than men
  • Lupus occurs primarily in women in their childbearing years
  • Lupus is 3 times more common in African-American women; it is also more common in women of Hispanic, Asian and Native American descent

    SPEAKERS:
    David M. Eisenberg, MD
    Osher Institute, Harvard Medical School
    Boston, MA

    Anthony Allison, MD
    SurroMed Inc.
    Menlo Park, CA

    Kevin G. Moder, MD
    Mayo Clinic
    Rochester, MN

    Victoria Werth, MD
    University of Pennsylvania
    Philadelphia, PA

    Betty Diamond, MD
    Albert Einstein College of Medicine
    Bronx, NY

    Bevra Hahn, MD
    David Geffen School of Medicine
    Los Angeles, CA

    WHEN AND WHERE:
    Thursday, October 21 12:30 PM
    Marriott Rivercenter Hotel
    Grand Ballroom, Salons H, K and L
    -end-
    FOR MORE INFORMATION/ ARRANGE INTERVIEWS:
    Jen Acer
    Ketchum
    732-266-4450 (on site during ACR)
    jennifer.acer@ketchum.com

    CJ Martinez
    Ketchum
    310-980-5431 (on site during ACR)
    cj.martinez@ketchum.com

    This symposium is supported by an unrestricted educational grant from Aspreva Pharmaceuticals.

    Ketchum UK

    Related Lupus Articles from Brightsurf:

    Systemic lupus erythematosus (SLE)
    If renal remission is achieved therapeutically in cases of lupus nephritis (LN), the 10-year survival rate increases significantly.

    Race-specific lupus nephritis biomarkers
    A University of Houston biomedical researcher has discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

    Lupus patients who take their medications lower their diabetes risk
    Patients with lupus who take their medications as prescribed have much lower odds of developing type 2 diabetes, a common complication of the disease, finds a new study from the University of British Columbia.

    Nearly 1 in 3 patients with lupus use prescription opioids for pain
    A new study finds nearly one in three adults with lupus use prescription opioids to manage pain, despite a lack of evidence that opioids are effective for reducing pain from rheumatic diseases.

    Developing therapeutic strategies for pregnant women with lupus
    A highly gender-biased disease, lupus afflicts females some nine times more than males.

    Lupus antibody target identified
    Researchers have identified a specific target of antibodies that are implicated in the neuropsychiatric symptoms of lupus, according to human research published in JNeurosci.

    B cells off rails early in lupus
    Emory scientists could discern that in people with SLE, signals driving expansion and activation are present at an earlier stage of B cell differentiation than previously appreciated.

    Can adverse childhood experiences worsen lupus symptoms?
    Adverse childhood experiences (ACEs) encompass traumas such as abuse, neglect, and household challenges.

    Unlocking the female bias in lupus
    The majority of lupus patients are female, and new findings from the University of Pennsylvania shed light on why.

    How a single faulty gene can lead to lupus
    IBS-AIM (Academy of Immunology and Microbiology) research team at Pohang University of Science and Technology (POSTECH) in South Korea has discovered the role of a key gene involved in the autoimmune disease systemic lupus erythematosus (SLE) or lupus for short.

    Read More: Lupus News and Lupus Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.